|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
FIBROZILS MAY DISPLACE THE DRUG FROM THEIR PROTEIN BINDING SITES, HENCE INCREASE THEIR PLASMA CONCENTRATION. SO DOSE OF THE DRUG SHOULD BE REDUCED
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
CO-ADMINISTRATION OF HMG-COA REDUCTASE INHIBITORS WITH DRUGS THAT CAUSE MYOPATHY WHEN GIVEN ALONE, SUCH AS FIBRATES ; COMBINED USE SHOULD BE AVOIDED BECAUSE OF INCREASED CHANCES OF MYOPATHY
|
CO-ADMINISTRATION OF HMG-COA REDUCTASE INHIBITORS WITH DRUGS THAT CAUSE MYOPATHY WHEN GIVEN ALONE, SUCH AS FIBRATES ; COMBINED USE SHOULD BE AVOIDED BECAUSE OF INCREASED CHANCES OF MYOPATHY
|
CO-ADMINISTRATION OF HMG-COA REDUCTASE INHIBITORS WITH DRUGS THAT CAUSE MYOPATHY WHEN GIVEN ALONE, SUCH AS FIBRATES ; COMBINED USE SHOULD BE AVOIDED BECAUSE OF INCREASED CHANCES OF MYOPATHY
|
CO-ADMINISTRATION OF HMG-COA REDUCTASE INHIBITORS WITH DRUGS THAT CAUSE MYOPATHY WHEN GIVEN ALONE, SUCH AS FIBRATES ; COMBINED USE SHOULD BE AVOIDED BECAUSE OF INCREASED CHANCES OF MYOPATHY
|
PROGESTERONES ENHANCES PLASMA CLEARANCE OF THE DRUG
|
PROGESTERONES ENHANCES PLASMA CLEARANCE OF THE DRUG
|
PROGESTERONES ENHANCES PLASMA CLEARANCE OF THE DRUG
|
PROGESTERONES ENHANCES PLASMA CLEARANCE OF THE DRUG
|
PROGESTERONES ENHANCES PLASMA CLEARANCE OF THE DRUG
|
PROGESTERONES ENHANCES PLASMA CLEARANCE OF THE DRUG
|
PROGESTERONES ENHANCES PLASMA CLEARANCE OF THE DRUG
|
PROGESTERONES ENHANCES PLASMA CLEARANCE OF THE DRUG
|
PROGESTERONES ENHANCES PLASMA CLEARANCE OF THE DRUG
|
PROGESTERONES ENHANCES PLASMA CLEARANCE OF THE DRUG
|